In five patients with venous thromboembolic disease treated with recombinant tissue-type plasminogen activator (rt-PA), there was a marked increase in the mean concentrations of fibrinopeptide A (from 0.6 to 5.9 nM; P < 0.0001) and desarginine fibrinopeptide B (from 5.6 nM to 24.1 nM; P < 0.01) 30 min after a bolus of rt-PA (0.6 mg/kg). Thrombin was unlikely to be responsible because the levels of desarginine fibrinopeptide B exceeded those of fibrinopeptide A and the changes occurred despite concomitant heparin therapy. The purpose of this study therefore, was to determine whether rt-PA directly releases the fibrinopeptides from fibrinogen. Incubation of rt-PA with heparinized plasma or purified fibrinogen resulted in time and dose-dependent release of both fibrinopeptide A and B. Contaminating thrombin was not responsible for this activity by the following criteria: the rate of rt-PA mediated fibrinopeptide B release was considerably faster than that of fibrinopeptide A, and fibrinopeptide release was unaffected by heparin, hirudin, or a monospecific antithrombin IgG. Aprotinin also had no effect on fibrinopeptide release, indicating that this activity was not plasmin mediated. Fibrinopeptide release was shown to be due to rt-PA because this activity was completely blocked by a monoclonal antibody against the enzyme. Further, the specificity of rt-PA for the thrombin cleavage sites on fibrinogen was confirmed by the demonstration that rt-PA released fibrinopeptide A or fibrinopeptide B from fibrinopeptide A or B-containing substrates, respectively. These studies thus demonstrate that (a) rt-PA releases fibrinopeptides A and B from fibrinogen thereby indicating that this enzyme is not specific for plasminogen, and (b) plasma fibrinopeptide A and desarginine fibrinopeptide B levels are not specific markers of thrombin action on fibrinogen in patients receiving rt-PA.
Introduction
Tissue-type plasminogen activator (t-PA)' is a trypsinlike ser- ine proteinase that activates plasminogen to plasmin thereby initiating fibrinolysis. Amounts of t-PA sufficient for clinical investigation have recently been produced in melanoma cell culture and by recombinant DNA techniques (rt-PA). Despite its affinity for fibrin (1, 2) and its enhanced enzymatic activity in the presence of this substrate (3, 4) , initial clinical studies in patients with acute myocardial infarction have demonstrated that t-PA administration is associated with a significant decrease in the plasma fibrinogen concentration (5) (6) (7) (8) (9) . These findings are not unexpected since theoretical calculations based on the reported kinetic parameters for the interaction between plasminogen and t-PA predicted that large doses of t-PA would result in systemic fibrinogenolysis (10, 11) .
In addition to fibrinogenolysis, a troublesome complication of thrombolytic therapy for acute myocardial infarction is early rethrombosis (12) (13) (14) (15) that can occur despite heparin (14, 15) , aspirin, or dipyridamole administration (15) . The etiology of reocclusion is unclear although high grade residual stenosis may be a contributing factor (16) . To determine the role of activation of the coagulation system in rethrombosis, investigators have measured plasma levels of fibrinopeptide A (FPA) after thrombolytic therapy as an index of in vivo thrombin activity. Based on the observation that plasma FPA levels increase after the administration of rt-PA or streptokinase, it has been hypothesized that thrombolytic therapy is associated with thrombin generation and that this contributes to the rethrombosis (17, 18) . Further, Owen et al. (18) concluded that thrombin produced in association with lytic therapy is generated at a site where it is protected from fluid-phase inhibitors since these investigators documented an increase in plasma FPA levels despite heparin administration. An alternate (and not mutually exclusive) explanation for these findings is that thrombolytic agents exert a direct effect on fibrinogen that results in fibrinopeptide release. This latter possibility is important not only because of its basic biochemical implications, but also because, if correct, it would put in question the validity of employing plasma FPA levels during thrombolytic therapy as a marker of thrombin activity.
In this study, patients with venous thromboembolic disease were treated with rt-PA. Despite concomitant heparin administration, rt-PA infusion was associated with a marked elevation in the plasma levels of both FPA and desarginine fibrinopeptide B (FPB) . Further, at each time point the levels of desarginine FPB exceeded those of FPA. Thrombin was unlikely to be responsible for the increase in peptide levels because the pattern of changes is not characteristic of thrombin action on fibrinogen (19, 20) , and because the changes occurred despite therapeutic doses of heparin. To explore the mechanism responsible for the increase in fibrinopeptide values, further experiments were performed to determine whether rt-PA has a direct effect on fibrinogen that results in fibrinopeptide release.
Methods
Reagents. Two preparations of human rt-PA were employed. Both consisted of predominantly single-chain material. The rt-PA administered to patients and used in the majority of our experimental studies was obtained from Genentech, Inc., San Francisco, CA (lot K905 1A6), and was cloned in a Chinese hamster ovarian cell line. The other rt-PA preparation (lot 118) was a gift from CODON, Inc., San Francisco, CA and was purified from a human melanoma cell line derived from RPMI 7932 that had been genetically modified to contain several copies of t-PA coding DNA. Unless otherwise stated, the rt-PA employed was the material produced by Genentech, Inc. Single-chain human melanoma cell t-PA (lot 28-04) and ESP 2, a monoclonal antibody against t-PA that has previously been shown to bind to t-PA and to inhibit its amidolytic and fibrinogenolytic activity (21) , were from American Diagnostica, Greenwich, CT. PMSF and D-Phe-ProArgCH2CI were from Sigma Chemical Co., St. Louis, MO, while aprotinin was from FBA Pharmaceuticals, New York. Human a-thrombin was a generous gift of Dr. J. Fenton, II, NY State Department of Health, Albany, NY.
A monospecific polyclonal sheep IgG against human thrombin was provided by Dr. F. Ofosu, McMaster Medical Centre, Hamilton, Ontario. Preliminary studies with this antibody demonstrated that at a concentration of 5 Mg/ml it inhibited > 98% of the FPA and FPB released from fibrinogen (0.6 mg/ml) by human a-thrombin (at concentrations ranging from 0.01 to 0.2 U/ml). The synthetic peptide analogues of FPA (Aa 1-15, Aa l-14, Aa 1-13, and Aa l-12) and of the NH2-terminal region of the Aa-chain of fibrinogen (Aa l-18, Aa 1-19, Aal-22, Aal-23, and Aal-28) were synthesized by R. Mumford of Merck Sharp and Dohme Research Laboratories, Rahway, NJ, using the solid-phase method of Merrifield (22) . Aal-20 and Aal-21 were synthesized by Dr. G. Wilner, Washington University, St. Louis, as previously described (23) .
Patients. After informed signed consent was obtained, five patients with angiographically documented pulmonary embolism and one patient with venographically confirmed axillary vein thrombosis were entered into a study of bolus dose rt-PA infusion. This study was approved by the Research Advisory Committees at the Hamilton Civic Hospitals and McMaster University.
All patients received an intravenous bolus of heparin (5,000 U) followed by a continuous heparin infusion at 1,200 U/h. The heparin dose was adjusted to maintain the activated partial thromboplastin time in the therapeutic range (1.5 to 2 times control). Once radiographic confirmation of venous thromboembolic disease was obtained, five of the six patients were given a single dose ofrt-PA (0.6 mg/kg ideal body wt reconstituted in 50 ml sterile water) by bolus injection over 2 min and were monitored closely for evidence of bleeding. An additional patient with angiographically documented pulmonary embolism was treated with two bolus injections of rt-PA (25 mg/dose) given 2 h apart. In all patients, the heparin infusion was continued throughout and was interrupted only for the 2-min interval(s) of rt-PA administration.
Blood collection and processing. Using a 21-gauge butterfly needle, blood samples were collected from an antecubital vein immediately before rt-PA injection and at 0.5, 1.5, and 3.0 h after the infusion. At each time point, blood was drawn into 5-ml vacutainer tubes (Becton Dickinson Co., Toronto, Ontario) prefilled with 50 Ml of D-Phe-ProArgCH2CI (100MgM diluted in 1 mM HCI). After careful mixing, 4.5 ml of blood was transferred into a second tube containing 0.5 ml of an anticoagulant solution consisting of 1,000 U/ml aprotinin, 1,400 U/ml heparin, 10 mM adenosine, and 20 mM theophylline in Hepes-buffered saline, pH 7.4. The red cells were then sedimented by centrifugation at 1,700 g for 15 min at 4°C and the plasma was harvested. Within 30 min of blood collection the fibrinogen in 2 ml plasma was precipitated by the addition of 6 ml ethanol followed by centrifugation at 4,000 g at 4°C for 20 min. The ethanol supernatants were evaporated to dryness in a Speed Vac Concentrator (Savant Instruments, Farmingdale, NY), reconstituted to original volume with distilled water and assayed for FPA and desarginine FPB immunoreactivity, as described below.
Radioimmunoassays. FPA was assayed as previously described (24) . Antiserum R2, employed throughout these studies, has previously been shown to be specific for FPA and to crossreact poorly with fibrinogen or FPA-containing fragments from the NH2-terminal region of the Aa-chain of fibrinogen (25-27). FPB was quantified as described elsewhere (20) (Fig. 1 ). This value is within the reported normal (24) and is consistent with previous reports ofrapid normalization ofFPA levels after heparin therapy for venous thromboembolic disease (33, 34) . In contrast, the mean plasma value for desarginine FPB before rt-PA infusion was 5.6 nM, whereas normal levels are < 0.6 nM (29) .
Despite the concomitant administration of therapeutic doses of heparin, there was an increase in the mean levels of FPA (from 0.6 to 5.9 nM) and desarginine FPB (from 5.6 to 24.1 nM) 30 min after rt-PA infusion. These differences are highly significant (P < 0.001 and P < 0.01, respectively) as determined by analysis of variance following log transformation of the data (35 Plasminogen activator-mediated fibrinopeptide release from fibrinogen. To determine whether rt-PA has a direct effect on fibrinogen resulting in fibrinopeptide release, rt-PA was incubated with heparinized plasma (Fig. 2 A) or with purified fibrinogen (Fig. 2 B) . This resulted in dose-dependent FPA and FPB release, and at each concentration of rt-PA used, the amount of FPB released was considerably higher than that of FPA. Thus, rt-PA cleaves both FPA and FPB from fibrinogen, 1702 Weitz, Cruickshank, Thong, Leslie, Levine, Ginsberg, and Eckhardt and in plasma this activity is unaffected by heparin. Further, the pattern of rt-PA mediated fibrinopeptide release is different from that produced by thrombin (19, 20) , and is characterized by cleavage of considerably more FPB than FPA.
The time course of fibrinopeptide release from purified fibrinogen illustrated in Fig. 3 HPLC analysis ofrt-PA mediatedproteolysis offibrinogen.
To confirm that the increase in FPA and FPB immunoreactivity following rt-PA incubation with fibrinogen represented release of the free fibrinopeptides, proteolysis also was monitored using HPLC. The products ofrt-PA mediated proteolysis were separated by reverse-phase HPLC (Fig. 4) . Single immunoreactive peaks were observed that coeluted with synthetic or native FPA and FPB, respectively. Effect of inhibitors and antibodies against thrombin and t-PA on rt-PA mediated fibrinopeptide release. To determine whether fibrinopeptide release by rt-PA was the result of a contaminating proteinase, the effect of a variety of inhibitors was investigated (Table II) Effect of inhibitors and antibodies against thrombin and rt-PA on FPA release by a mixture ofrt-PA and thrombin. To further exclude the possibility that rt-PA is contaminated with trace amounts of thrombin, the effect of a variety of inhibitors on fibrinopeptide release mediated by a mixture of thrombin and rt-PA was investigated (Table IV) . Incubation of fibrinogen (0.6 mg/ml) with a-thrombin (4.0 X 10-' U/ml) resulted in FPA release similar in amount to that produced by 16 ,g/ml of rt-PA (28.9 and 26.5 pmol, respectively). When a mixture of thrombin and rt-PA was incubated with fibrinogen there was an additive effect on FPA release. The addition of hirudin or a monospecific antithrombin IgG decreased by approximately half the amount of FPA released by the proteinase mixture. ESP 2, a monoclonal antibody against t-PA, had a similar effect on peptide release. In contrast, the addition of PMSF or D-Phe-Pro-ArgCH2Cl totally blocked FPA release. These studies thus confirm that rt-PA mediated FPA release is not the result of contaminating thrombin. Results shown represent the mean data from two separate experiments. Fibrinogen (0.6 mg/ml) was incubated with a mixture of rt-PA (16 pg/ml) and ca-thrombin (4.04 X IO-' U/ml) for 2 h at 37°C in the presence and absence of inhibitors and antibodies against thrombin or t-PA. The reactions were stopped and the fibrinogen precipitated by the addition of ethanol, and the ethanol supernatants were then assayed for FPA immunoreactivity.
rt-PA mediated peptide release from FPA-and FPB-containing substrates. To further explore the specificity of rt-PA for the Aa (Fig. 5) . In contrast, proteolysis of B#l1-42 yielded a single peak of FPB immunoreactivity that coeluted with synthetic FPB (data not shown). These studies confirm the specificity of rt-PA for the thrombin cleavage sites.
Discussion
Our findings confirm a previous report that rt-PA administration is associated with an increase in plasma FPA levels (18) and demonstrate that this increase occurs despite concomitant heparin administration. We have extended these observations by demonstrating that plasma values of desarginine FPB also are elevated after rt-PA infusion, and that the levels of this peptide are higher than those of FPA, both before and after rt-PA administration (Fig. 1) . Finding increased desarginine FPB levels before rt-PA infusion is unexpected since the patients were receiving heparin therapy and plasma FPA values were within the normal range. This suggests that an enzyme other than thrombin is responsible for FPB release. The finding that desarginine FPB levels remain higher than those of FPA after rt-PA infusion further supports this concept since this pattern is not characteristic of thrombin action on fibrinogen.
Confirmation that FPA and desarginine FPB immunoreactivity in patient samples represented the free peptides (and not some other cross-reacting fibrinogen-derived fragments) came from the HPLC demonstration that the immunoreactive fractions coeluted with native or synthetic FPA and desarginine FPB, respectively. Further, epitope mapping studies (Table I) validate previous reports (25) (26) (27) (Figs. 2 and 3) , thrombin results in more rapid FPA release from fibrinogen (19, 20) . Second, rt-PA-mediated fibrinopeptide release occurs in the presence of the thrombin inhibitors, heparin (Fig. 2 A) and hirudin (Table II) , and release is unaffected by a monospecific antithrombin IgG (Table III) . Third, fibrinopeptide release mediated by a mixture of thrombin and rt-PA is decreased by half following the addition of hirudin, an antithrombin IgG or a monoclonal antibody against t-PA ( Table IV) . Inhibiting that component of fibrinopeptide release induced by thrombin (with hirudin or with an antithrombin IgG) thus has no effect on the rt-PA-mediated component of peptide release. Finally, plasmin is not responsible for fibrinopeptide release since aprotinin has no effect on this activity (Table II) . Further, plasmin releases BB1-42 from fibrinogen (30) , rather than EPA or FPB, and no B#lB -42 was detected in the digestion mixture.
The evidence that t-PA cleaves FPA and FPB from fibrinogen comes from the demonstration that immunodepletion of rt-PA using a monoclonal antibody against t-PA abolishes rt-PA mediated fibrinopeptide release (Table III) . Further, rt-PA releases FPA and FPB from Aa1-21 ( Fig. 5 ) and BB1-42, respectively, thereby confirming the specificity of rt-PA for the thrombin cleavage sites on FPA and FPB-containing substrates. Finally, fibrinopeptide release is effected by rt-PA cloned from two different cell lines and by human melanoma cell derived t-PA, indicating that this activity is a function of t-PA derived from a variety of sources.
The interaction between rt-PA and fibrinogen that results in fibrinopeptide release depends on the active-site serine of rt-PA since peptide release is inhibited by PMSF (Table II) Fraction Number Figure 5 . (40, 41) or stimuli associated with venous stasis (42) . The neutrophil proteinase, elastase, also may contribute since this enzyme is released from neutrophils during the blood coagulation process (43) and has the potential to attack the NW2-terminal region of the BB-chain of fibrinogen resulting in increased desarginine FPB immunoreactivity (44) without an increase in FPA (23) . The extent of elevation and the persistent increase in fibrinopeptide levels after rt-PA administration is difficult to explain given the short half-lives of t-PA (45, 46) and the fibrinopeptides (24, 29) , and the relatively slow rates of rt-PAmediated fibrinopeptide release in vitro. The binding of functionally active t-PA to endothelial cells (47) however, may serve to localize and protect the enzyme from its inhibitors thereby prolonging its duration of action and increasing its enzymatic potential. This possibility deserves further study.
In summary, these studies demonstrate that t-PA has enzymatic specificity for a macromolecular substrate other than plasminogen and cleaves the thrombin susceptible bonds on fibrinogen. Accordingly, plasma FPA and desarginine FPB levels are not specific markers of thrombin action on fibrinogen in patients receiving thrombolytic therapy with rt-PA.
